{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:22:43Z","timestamp":1769016163743,"version":"3.49.0"},"reference-count":17,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2020,9,29]]},"DOI":"10.1536\/ihj.20-162","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T22:05:03Z","timestamp":1599861903000},"page":"1070-1074","source":"Crossref","is-referenced-by-count":27,"title":["A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma"],"prefix":"10.1536","volume":"61","author":[{"given":"Hotaka","family":"Matsui","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taketo","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motofumi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bellmunt J, de Wit R, Vaughn DJ, <i>et al<\/i>. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015-26.","DOI":"10.1056\/NEJMoa1613683"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yang S, Asnani A. Cardiotoxicities associated with immune checkpoint inhibitors. Curr Probl Cancer 2018; 42: 422-32.","DOI":"10.1016\/j.currproblcancer.2018.07.002"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Johnson DB, Balko JM, Compton ML, <i>et al<\/i>. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375: 1749-55.","DOI":"10.1056\/NEJMoa1609214"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Frigeri M, Meyer P, Banfi C, <i>et al<\/i>. Immune checkpoint inhibitor-associated myocarditis: A new challenge for cardiologists. Can J Cardiol 2018; 34: 92.e1-3.","DOI":"10.1016\/j.cjca.2017.09.025"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nasr F, El Rassy E, Maalouf G, <i>et al<\/i>. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 2018; 91: 171-3.","DOI":"10.1016\/j.ejca.2017.11.026"},{"key":"6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/01676830.2018.1490439","volume":"38","year":"2019","unstructured":"6. Hellman JB, Traynis I, Lin LK. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia. Orbit 2019; 38: 244-7.","journal-title":"Orbit","ISSN":"https:\/\/id.crossref.org\/issn\/0167-6830","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. L\u00e4ubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015; 3: 11.","DOI":"10.1186\/s40425-015-0057-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mahmood SS, Fradley MG, Cohen JV, <i>et al<\/i>. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018; 71: 1755-64.","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Huh SY, Shin SH, Kim MK, Lee SY, Son KH, Shin HY. Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer. J Clin Neurol 2018; 14: 115-7.","DOI":"10.3988\/jcn.2018.14.1.115"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Vallet H, Gaillet A, Weiss N, <i>et al<\/i>. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol 2016; 27: 1352-3.","DOI":"10.1093\/annonc\/mdw126"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tay SH, Wong AS, Jeyasekharan AD. A patient with pembrolizumab-induced fatal polymyositis. Eur J Cancer 2018; 91: 180-2.","DOI":"10.1016\/j.ejca.2017.12.019"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gandiga PC, Wang AR, Gonzalez-Rivera T, Sreih AG. Pembrolizumab-associated inflammatory myopathy. Rheumatology 2018; 57: 397-8.","DOI":"10.1093\/rheumatology\/kex346"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: A fatal case report. J Oncol Pharm Pract 2018; 24: 146-9.","DOI":"10.1177\/1078155216687389"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment. J Immunother 2017; 40: 221-3.","DOI":"10.1097\/CJI.0000000000000172"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: Emerging immune-mediated myopathies. J Immunother 2018; 41: 208-11.","DOI":"10.1097\/CJI.0000000000000196"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fellner A, Makranz C, Lotem M, <i>et al<\/i>. Neurologic complications of immune checkpoint inhibitors. J Neurooncol 2018; 137: 601-9.","DOI":"10.1007\/s11060-018-2752-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Uchio N, Taira K, Ikenaga C, <i>et al<\/i>. Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology. Neurol Neuroimmunol Neuroinflamm 2019; 6: e535.","DOI":"10.1212\/NXI.0000000000000535"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/5\/61_20-162\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T03:56:43Z","timestamp":1601697403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/5\/61_20-162\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-162","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}